CD4 and neoplasm: The results showed that rAd-IL-2 significantly stimulated tumor-specific cytotoxic T lymphocyte responses by inducing the recruitment of CD4+ and CD8+ T cells to tumors, leading to tumor regression and long-term survival of mice during the 120-day treatment period.